Thus, with these new technologies emerging, it is of great interest to understand whether the IL-33/amphiregulin/EGFR axis can act directly or indirectly to retain beta cell function during T1D, and whether amphiregulin should be further pursued as a therapeutic target for T1D. Here, AREG is linked to type 1 diabetes mellitus.